Evidence for the presence of the type 2 corticotropin releasing factor receptor in the rodent cerebellum
✍ Scribed by Georgia A. Bishop; Jin Bin Tian; Jennifer J. Stanke; Andy J. Fischer; James S. King
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 989 KB
- Volume
- 84
- Category
- Article
- ISSN
- 0360-4012
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Corticotropin releasing factor (CRF), localized in afferent inputs to the cerebellum, binds to two receptors defined as the Type 1 (CRF‐R1) and the Type 2 (CRF‐R2α). CRF‐R1 has been localized to the cerebellum, as has a truncated isoform of CRF‐R2α. Evidence for the presence of the full length isoform of CRF‐R2α in the cerebellum is conflicting. We used RT‐PCR, immunohistochemical, and physiologic techniques to resolve this conflict. RT‐PCR data show low levels of CRF‐R2α in the vermis and hemisphere of the cerebellum. These observations were confirmed by the Gene Expression Nervous System Atlas (GENSAT) database. A CRF‐R2α antibody was used to determine the cellular distribution of the receptor in the cerebellum. The vast majority of the receptors are localized to Bergmann glial cells located throughout the cerebellum, as well as astrocytes in the granule cell layer. Neuronal labeling is present in sub‐populations of Purkinje cells, Golgi cells, basket cells, and cerebellar nuclear neurons. Physiologic data show that urocortin II, which binds selectively to CRF‐R2α, increases the firing rate of both Purkinje cells and nuclear neurons; this response can be blocked by the CRF‐R2α‐specific antagonist, antisauvagine‐30. The present results confirm that CRF‐R2α is present in the cerebellum and functions in circuits that modulate the firing rate of Purkinje cells and cerebellar nuclear neurons. A comparative analysis showed that the patterns of distribution of CRF‐R1, CRF‐R2α and CRF‐R2α‐tr are distinct. These data indicate that the CRF family of peptides modulates cerebellar output by binding to multiple CRF receptors. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract Corticotropin‐releasing factor agonists exert inhibitory effects in stomach functions possibly through peripheral routes. We have previously reported the expression of Urocortin (Ucn) I, an endogenous ligand of both CRF receptor types CRF~1~ and CRF~2~, in the human stomach. We examined
## Abstract Corticotropin releasing factor (CRF) and its cognate receptors, defined as Type 1 and Type 2 have been localized within the cerebellum. The Type 2 CRF receptor (CRF‐R2) is known to have both a full length (CRF‐R2α) and a truncated (CRF‐R2α‐tr) isoform. A recent study documented CRF‐R2α
Corticotropin releasing factor (CRF), the most important regulator of various responses to stress, acts through CRF receptors (CRFR). For their characterization in brain tissue of Sprague-Dawley rats and C57BL/6J mice, a recently described polyclonal antibody directed against the N-terminus of rat C
Experimental findings have recently suggested a toxic role for glucocorticoids in hippocampus, the main brain target for the adrenocortical hormones. In this study, we explored the activity of the hypothalamuspituitary-adrenal (HPA) axis in a group of patients with dementia of the Alzheimer's type (